Back to News
Market Impact: 0.15
Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026
Source: PR Newswire
Healthcare & Biotech
Lundbeck announced a late-breaking Phase III MASCOT oral presentation on amlenetug, its investigational treatment for multiple system atrophy (MSA). The presentation will characterize the ongoing global trial's clinical profile and participant diversity, alongside research on trial endpoints, biomarkers and diagnostics. No efficacy, safety, or financial results were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
HLUN.B0.35
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Recent lobbyist for Palantir had key role in helping Andy Burnham become PM
- A $30 Billion Healthcare Funding Problem Is Dividing California
- Liquidia stock price target cut to $58 by H.C. Wainwright on patent uncertainty
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Software for Buy-Side Teams: Build the Research Stack
- Augmented Intelligence: AllMind, Elevate Human Judgement With an Accessible, Powerful, Data-Driven Financial AI Toolkit